The PARITY team is thrilled to announce that the trial has reached a major milestone! On December 21st, the 200th participant was enrolled in the study. This is a very exciting time for the PARITY team as this number represents one-third of the total enrolment target. The New Year promises several new international sites and a protocol amendment to expand the eligibility criteria, both of which should help increase the pace of enrolment. On behalf of the entire PARITY team, we hope you have a happy and safe holiday season … and all the best in 2017!
Congratulations to Dr. Tim Damron and Tina Craig at SUNY Upstate University Hospital (Syracuse, NY) for enrolling their first (of hopefully many) PARITY participant on 1 December 2016! Thank you for your continued efforts in this study – we very much appreciate your hard work!
On Thursday, December 1, the PARITY Symposium entitled ‘Strategies to prevent infection in endoprosthetic reconstruction’ was held at the Bone and Soft-Tissue Tumors (BSTT) Course in Madrid, Spain. Dr. Michelle Ghert gave a talk and led discussions on peri- and intra-operative strategies to prevent surgical site infections, as well as what the PARITY trial is doing to help answer the question about the appropriate duration of prophylactic antibiotics.
On Thursday, December 1st from 6:30 – 7PM, Dr. Michelle Ghert and Dr. Robert Quinn will be giving talks and leading discussions during the PARITY Symposium entitled “Strategies to prevent infection in endoprosthetic reconstruction” at the Bone and Soft-Tissue Tumors Course in Madrid, Spain. Peri-operative and intra-operative strategies will be discussed, as well as a period for discussion and questions. The Bone and Soft-Tissue Tumors Course is taking place in the Aula Magna at the Hospital Universitario La Paz. All individuals attending this course are invited to attend this special event.
To register for the Bone and Soft-Tissue Tumors Course, please visit the following website: www.bstt-madridcourse.com.
We look forward to seeing you there!
The PARITY Methods Centre team is thrilled to announce that the Instituto de Ortopedia e Traumatologia in São Paulo, Brazil enrolled the 150th study participant on Tuesday, June 7, thereby reaching 25% of the study’s total enrolment target. There are currently 36 sites open to enrolment across Canada, the United States, Australia, Argentina, Brazil, South Africa and Spain.
Please extend your congratulations to Dr. André Mathias Baptista, Dr. Juan Pablo Zumárraga, and the study team at Instituto de Ortopedia e Traumatologia da Universidade de São Paulo for enrolling this latest study participant.
We would like to extend a warm welcome to Dr. Roberto Vélez, Dr. Manolo Perez, Dr. Mario Aguirre, and Alba López at Hospital Vall d’Hebron, which is the latest site to attain enrolment-ready status and is the first European site to participate in the trial. There are currently 35 sites actively screening and enrolling patients into the PARITY trial across 7 countries (Canada, the United States, Australia, Argentina, South Africa, Brazil and Spain).
We would also like to thank Dr. Vélez for his dedication to the study and his oversight of the European start-up process! We will continue to update European sites that have expressed an interest in participating in PARITY as we continue to complete the necessary steps in order to initiate the trial throughout Europe.
The PARITY Methods Centre team visited the Instituto de Ortopedia e Traumatologia da Universidade de São Paulo in Brazil earlier this week with the goal of completing the start-up phase and training the site personnel on the study’s operating procedures. While in São Paulo, the PARITY team also met with another Brazilian collaborator who has expressed an interest in participating in the trial to strategize a site specific plan for study initiation. There are now 34 sites open to enrolment across Canada, the United States, Australia, Argentina, South Africa and Brazil.
We would like to thank Dr. André Mathias Baptista, Dr. Juan Pablo Zumárraga and Dr. Ricardo Becker for their hospitality and taking the time out of their busy schedules to accommodate our trip. We very much look forward to working with all of you!
The PARITY Methods Centre team is thrilled to announce that the PARITY trial enrolled its 120th participant on Tuesday, December 8, thereby reaching 20% of its total enrolment target. There are currently 33 sites open to enrolment across Canada, the United States, Australia, Argentina and South Africa.
Please extend your congratulations to Dr. Robert Turcotte, Dr. Krista Goulding, and Firas Dandachli at McGill University Health Centre for enrolling the 120th PARITY participant!
We would like to extend a warm welcome to Dr. Reitze Rodseth, Dr. Leonard Marais, Dr. Chantal Rajah and Simphiwe Gumede at Grey’s Hospital for joining the PARITY team. Grey’s Hospital in Pietermaritzburg, South Africa is the latest PARITY site to attain enrolment-ready status and is the first African site to participate in the trial. There are currently 33 sites actively screening and enrolling patients into the PARITY trial across 5 countries and 4 continents (Canada, the Unites States, Australia, Argentina and South Africa).
Thank you for your continued efforts to get your site onboard!
On Saturday, October 10th from 6:30 – 8AM Eastern Daylight Time, a focus group for the PARITY sub-study entitled “Collaborative prospective research in rare cancers: A qualitative study to determine factors that drive a paradigm shift in the research landscape” will be taking place. The focus group will be held in Cordova 3 Meeting Room at the JW Marriott Orlando Grande Lakes Hotel. A buffet breakfast will be served.
All co-investigators and study coordinators are invited to attend. Please also encourage all individuals interested in being involved in the PARITY trial to attend.
If you have any questions concerning this meeting, please feel free to contact Tricia at the Methods Centre (firstname.lastname@example.org or 905-527-4322 ext. 44983).
We look forward to seeing you in Orlando!